Stay ahead of the game: Early intervention with disease modifying treatment for MS with Prof Klaus S
Stay ahead of the game: Early intervention with disease modifying treatment for MS with Prof Klaus S
0+ APD
Global Rank
TOP 1%
Creator:
Dr Agne Straukiene
- Health & Fitness
- Human Resources
- Recruitment
Become a Verified PARTNER.FM Member:
By joining PARTNER.FM, you become part of a vibrant community of podcasters who are passionate about their craft. As a verified member, you gain access to exclusive benefits and opportunities. Let's set you apart from the rest!
Increase the Visibility of Your Podcast:
Stand out in the crowded podcast landscape! List your podcast on our platform to gain exposure and attract a broader audience. Our dedicated marketing team is here to promote your content, helping you reach new heights.
Get Matched with Brands (It's Free)
Monetize your podcast through brand partnerships. We connect you with relevant brands seeking collaborations, enabling you to showcase your unique voice to their target audience. It's an excellent opportunity to grow your podcast while maintaining authenticity.-
Podcast Promotional Options
-
Partner Up
Guest Interview
-
Partner Up
Sponsored Interview
-
Partner Up
Promotional Codes (alpha)
-
Partner Up
Creative Integration
-
Partner Up
Brand Review
-
Partner Up
Episode Sponsorship
-
Partner Up
Pre Roll Ads
-
Partner Up
Mid Roll Ads
-
Partner Up
Post Roll Ads
Podcast data
Created By Dr Agne StraukienePodcast Status activeStarted 22/11/2022Latest Episode 22/11/2022Release Period EpisodicEpisodes 1Partner Reviews 0Language EnglishFrequency 0Average Length 46 minutes and 6 secondsCountry United StatesGlobal Rank TOP 1%Description
My guest in this episode is Prof Klaus Schmierer, Professor of Neurology at the Blizard Institute, Queen Mary University of London, and Consultant Neurologist at The Royal London Hospital, Barts Health NHS Trust, where he is the Research Lead for Neurology, Clinical Lead of the Day Case Unit, and BartsMS.
Prof Schmierer explains the important connection between healthy lifestyle and brain health. Prof Schmierer tells us what does that mean brain health to him personally.
During this interview we covered evidence based reasoning for early access to highly effective disease modifying therapies( DMT) for Multiple sclerosis, what are changes in managing MS disease these days and what is personalised care plan and treatment living with this condition. First impression what we consider may be mild MS , actually is not necessary a mild or benign MS. We discussed about MS that it can be treated as effectively and in timely manner as stroke these days. We discussed Ectrims(The European Committee for Treatment and Research in Multiple Sclerosis) international congress 2022 highlights of MS treatments including HCST. We discussed that MS is overall one disease and current classification RRMS
(relapsing remitting MS), SPMS ( Secondary progressive MS), PPMS ( Primary progressive MS), CIS ( Clinically isolated syndrome/first attack of MS), RIS( Radiologically isolated syndrome/ only changes on MRI scan) may be misleading. Is it worth treating RIS patients? There might be a hope for the whole MS community if we are treating early just before MS starts showing all signs and early symptoms. We discovered what inspires Prof Schmierer to implement changes and updates at his MS service, and also run MS Research efficiently and improve quality of life for people with MS.
More information about new clinical trial #attackMS which is open for recruitment email for more information: bartshealth.attackms@nhs.net -
-
Episodes
-
#636758 - Stay ahead of the game: Early intervention with disease modifying treatment for MS with Prof Klaus Schmierer
2 years ago
-
-
Reviews
- There are no reviews yet
-
Podcasts like this
-
View Podcast
- Fitness
- Health & Fitness
- Alternative Health
-
View Podcast
- Self-Help
- Books
- Health & Fitness
- News
-
View Podcast
- Personal Finance
- Self-Help
- Business
- Health & Fitness
-
View Podcast
- Sports
- Wilderness
- Health & Fitness
- Running
-
